will help China enhance its management of rare diseases, improve the diagnosis and treatment of rare diseases, and safeguard the health-related rights of patients with rare diseases. The CRDL will serve as a reference for relevant government agencies and ministries in the future. Thus far, rare diseases have not been officially defined in China. The definition in popular use was based on a consensus of experts reached by the Genetics Branch of the Chinese Medical Association in May 2010. According to this definition, a rare disease is a disease with a prevalence of less than 1/500,000 or a neonatal morbidity of less than 1/10,000 (3) . Since epidemiological data on rare diseases are lacking in China, the current list of rare diseases is based on actual conditions, and the list is mainly derived from the professional opinions of the Expert Committee on the Diagnosis, Treatment, and Care for Rare Diseases established by the Medical Administration Bureau of the former National Health and Family Planning Commission.
As early as 2016, the Shanghai Health and Family Planning Commission published the first local list of rare diseases in China entitled The List of Major Rare Diseases in Shanghai (2016 Edition) . The Shanghai list which includes 56 rare diseases, 50 of which are also included in the CRDL (4). On September 23
Summary
Over the past few years, the Chinese Government has paid greater attention to rare diseases and it has incorporated rare diseases in national health strategy and planning. On May 22, 2018, the Chinese Government officially released its first list of rare diseases, which included 121 rare diseases. The list was published to facilitate greater societal awareness of rare diseases, to improve the ability of front-line medical staff to treat rare diseases, to introduce incentives for research and development of orphan drugs, and to increase the availability of medicines for rare diseases. This effort will enhance the management of rare diseases in China, raise the level of diagnosis and treatment for rare diseases, and safeguard the healthrelated rights and interests of patients with rare diseases. The classification of rare diseases is based on a common international standards, which will promote international cooperation in drug research and policymaking with regard to rare diseases. Currently, there are no specific policies on rare diseases or orphan drugs nationwide, but the area of rare diseases has received increasing attention in recent years. The central government has included rare diseases in major health planning and strategy, including the five-year plan on public healthcare (2016-2020) (6) and the "Healthy China 2030" Planning Outline (7) . Local government has actively promoted care for rare diseases. In Qingdao, a city in Shandong Province, medical insurance has covered Behcet syndrome, multiple sclerosis, and myasthenia gravis since 2005 (8) . In Shanghai, the Children's Hospitalization Fund has covered Pompeii disease, Gaucher's disease, mucopolysaccharidosis, and Fabry disease since 2011 (9) . In Zhejiang Province, medical insurance has covered Gaucher's disease, amyotrophic lateral sclerosis, and phenylketonuria since 2016 (10). 60  61  62  63  64  65  66  67  68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84  85  86  87  88  89  90  91  92  93  94  95  96  97  98  99  100  101  102  103  104  105  106  107  108  109  110  111  112  113  114  115  116  117  118  119  120 Issuance of the CRDL has resolved the issue of "no official definition, no specific policy support, and no coverage by medical insurance" of rare diseases in China. The list facilitates greater societal awareness of rare diseases, it improves the ability of medical personnel to diagnose and treat rare diseases, it furnishes incentives for research and development of orphan drugs, and it increases the affordability of orphan drugs. The classification of rare diseases is based on an international consensus, which is sure to promote international cooperation in clinical trials and healthcare policymaking in the area of rare diseases.
